Taken together, our data strongly suggest that the HIF2α/CD36 pathway could have a pathogenic role in the phase of hepatosteatosis, but further investigation is needed for understanding in depth its impact on NASH progression. Here, CD36 is linked to metabolic dysfunction-associated steatohepatitis.